CD8A and neoplasm: [348] demonstrated that compared with conventional MTD regimens, a dose‐dense CT protocol (cisplatin+PTX) enhanced macrophage recruitment and tumor‐specific CD8+ T cell responses in a murine ovarian cancer model.